ARMISTICE CAPITAL, LLC Buys Co-Diagnostics Inc (CODX) -- Shares Look 33% Undervalued on GF Value
Armistice Capital, LLC recently acquired a new position of 559,706 shares in Co-Diagnostics Inc (CODX), valuing the transaction at $3.10 per share. Despite this, CODX shares have dropped significantly since the purchase, and the company faces severe financial challenges, including unprofitability and weak growth metrics. While GuruFocus indicates the stock might be 33% undervalued, it also labels it a "Possible Value Trap," cautioning investors due to deteriorating fundamentals.
ARMISTICE CAPITAL, LLC Acquires Shares of Decoy Therapeutics Inc (DCOY)
ARMISTICE CAPITAL, LLC recently acquired 65,503 shares of Decoy Therapeutics Inc (DCOY) at $7.19 per share, representing a new holding for the firm. Since the transaction on June 30, 2026, the stock has declined significantly by 53.69% to $3.33, highlighting the high-risk nature of this pre-clinical biotechnology company with severe financial strain and poor performance indicators. Despite a solid balance sheet rank, the company's lack of revenue and negative profitability make it a speculative investment.
Incyte Corp's R&D Head Pablo J. Cagnoni Sells 10,801 Shares via 10b5-1 Trading Plan
Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp, sold 10,801 shares of company stock on August 19, 2026, for $125.56 per share. This transaction was executed under a Rule 10b5-1 trading plan. Following the sale, Cagnoni's direct beneficial ownership in Incyte Corp stands at 183,200 shares, which includes unvested restricted and performance stock units.
Incyte (INCY) R&D head sells 10,801 shares, holds 183,200 in awards
Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp (INCY), sold 10,801 shares of common stock on August 19, 2026, for $125.56 per share under a Rule 10b5-1 trading plan. Following this transaction, he retains rights to 183,200 shares from unvested restricted stock units and earned performance stock units. This insider sale is considered to have a "Very High" filing impact and "Negative" sentiment.
H.C. Wainwright reiterates Incyte stock rating on cancer trial data
H.C. Wainwright has reiterated a Buy rating and $150 price target for Incyte (NASDAQ: INCY) following a review of clinical trial data for its experimental cancer treatment, INCB161734. The firm highlighted promising response rates for the drug when combined with chemotherapy regimens, noting its performance is within an early response range compared to a competitor. Incyte also reported strong Q2 2026 results, surpassing analyst expectations for EPS and revenue, and raising its full-year sales guidance, with analysts like Guggenheim and H.C. Wainwright increasing their price targets.
Incyte (NASDAQ:INCY) Receives Buy Rating from HC Wainwright
HC Wainwright has reiterated a "buy" rating for Incyte (NASDAQ:INCY) and maintained a $150 price target, suggesting a 16.76% upside. This follows Incyte's strong quarterly results, which surpassed analyst expectations with an EPS of $3.09 and revenue of $1.67 billion, a 37.7% increase year-over-year. Despite the positive outlook from HC Wainwright, overall analyst sentiment remains mixed, with an average "Hold" rating and a consensus target price of $123.10 among 24 analysts.
H.C. Wainwright reiterates Incyte stock rating on cancer trial data By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $150 price target for Incyte (NASDAQ: INCY) following a review of clinical trial data for its experimental cancer treatment, INCB161734. The stock is currently trading near its 52-week high, having gained 49% over the past year, and is considered undervalued by InvestingPro analysis. Recent second-quarter 2026 results also showed strong performance, exceeding analyst expectations and leading to raised full-year sales guidance.
Canaccord Genuity Initiates Incyte at Buy With $152 Price Target
Canaccord Genuity has initiated coverage on Incyte (INCY) with a Buy rating and a price target of $152. This news follows a series of other analyst adjustments for Incyte, with various firms maintaining or adjusting their ratings and price targets in August. The pharmaceutical company specializes in R&D for cancer and inflammatory disorders, with product sales making up the majority of its revenue.
INCY Looks 19.9% Overvalued on GF Value™ as Insider Selling Persists
Incyte Corp (INCY) is preparing to present updated clinical data on its KRAS G12D inhibitor, ?734, at the upcoming ESMO conference. While the company holds a strong GF Score™ of 87/100 and positive guru buying trends, GuruFocus’ GF Value™ indicates a modest overvaluation of 19.9%, suggesting limited margin of safety. Significant insider selling totaling $54.3 million over the past 12 months adds a layer of caution for investors.
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data
Neurocrine Biosciences (NBIX) is potentially 28% undervalued according to a recent analysis, following positive KINECT-PRO Phase 4 results for its drug INGREZZA. Despite a recent share price dip, NBIX has shown strong long-term returns and has a diverse CNS pipeline, suggesting significant future growth potential. However, the valuation hinges on successful execution for INGREZZA and CRENESSITY, with risks from pricing pressure and higher SG&A.
Incyte Corp. stock outperforms competitors on strong trading day
Shares of Incyte Corp. (INCY) rose 2.78% to $123.50 on Monday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average fall. This increase snapped a four-day losing streak for the company's stock.
Global Vitiligo Foundation Applauds Incyte’s "Moments of Clarity" Campaign for Elevating Patient Voices and Advancing Vitiligo Awareness
The Global Vitiligo Foundation (GVF) has lauded Incyte's "Moments of Clarity" campaign for its effective elevation of patient voices and its role in advancing vitiligo awareness. The campaign features authentic narratives from individuals with nonsegmental vitiligo, highlighting their journeys and the impact of treatment like Opzelura® (ruxolitinib) cream. GVF emphasizes that this initiative helps break down stigma, promotes informed care, and fosters a sense of community and empowerment among those affected by vitiligo.
Incyte stock holds at the $120 mark as strong quarterly earnings support valuation
Incyte stock is holding steady around the $120 mark, supported by strong quarterly earnings that significantly beat analyst expectations and double-digit revenue growth. Despite the positive financial performance, the stock carries a "Hold" consensus rating and is trading close to its average target price, suggesting that much of the recent fundamental progress may already be priced in. Investors are now looking to future pipeline milestones or additional earnings surprises to justify a material re-rating.
55,370 Shares in Incyte Corporation $INCY Bought by Summit Global Investments
Summit Global Investments recently acquired 55,370 shares of Incyte Corporation, valued at approximately $6.28 million, as part of a trend where institutional investors hold a significant 96.97% of the stock. Incyte reported strong Q2 earnings, beating EPS and revenue estimates, though EVP Patrick A. Mayes sold over 41,000 shares. The stock currently holds a "Hold" rating from analysts with an average price target of $120.65.
Baird Chautauqua Global Growth Fund's Incyte Corp(INCY) Holding History
The Baird Chautauqua Global Growth Fund holds 174,406.00 shares of Incyte Corp (INCY), valued at $19.77 million, which represents 4.49% of their portfolio. The fund has made 21 purchases of INCY since 2019Q3 at an average price of $81.95, and one sale at $71.31. Based on the current price of $120.16, the fund has an estimated gain of $6.66 million, or 46.49%.
Incyte Corp's Pablo J. Cagnoni Sells 10,803 Shares Under Rule 10b5-1 Plan in August 2026
Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp (NASDAQ: INCY), sold 10,803 shares of common stock on August 12, 2026, for $120.04 per share under a prearranged Rule 10b5-1 trading plan. After this transaction, Cagnoni beneficially owns 194,001 shares, including 183,200 unvested restricted and performance stock units. The Form 4 filing with the SEC details this open-market sale.
MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise
MacroGenics reported a Q2 2026 profit driven by an $86.1 million gain from the sale of its CDMO operations for approximately $119.6 million. The company's total revenue significantly increased to $32.8 million due to a $24.5 million milestone from Sanofi and higher ZYNYZ royalty revenue, extending its cash runway through 2028 despite ongoing losses from its core operations.
Incyte Corp (INCY) R&D chief sells 10,803 shares under Rule 10b5-1 plan
Incyte Corp's President, Global Head of R&D, Pablo J. Cagnoni, sold 10,803 shares of common stock at $120.04 per share on August 12, 2026, under a Rule 10b5-1 trading plan. Following this transaction, Cagnoni directly holds 194,001 shares, which includes 183,200 shares from unvested restricted and performance stock units. This insider sale was executed as a pre-arranged trade.
Bernstein Lifts Regeneron Price Target to $756, Stays on Sidelines
Bernstein has raised its price target for Regeneron Pharmaceuticals to $756 from $753, while maintaining a Market Perform rating, indicating a slightly more positive near-term outlook but not a fundamental shift in its investment thesis. This new target remains below the Wall Street consensus of $838.80, suggesting Bernstein sees less upside compared to other analysts. The firm also adjusted Incyte's price target to $104 from $99, also with a Market Perform rating, reflecting a cautious stance on biotech valuations generally.
It's crunch time for Karyopharm as company faces potential default next month
Karyopharm Therapeutics is facing a potential default next month due to depleted cash reserves and an upcoming debt payment. The company reported a significant loss in Q2 and has limited liquidity, but is negotiating with lenders and exploring financing and strategic alternatives. Karyopharm is also pursuing accelerated approval for an Xpovio label expansion for myelofibrosis, hoping to leverage existing infrastructure despite stagnant Xpovio sales and recent layoffs.
MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner
MacroGenics reported its second quarter 2026 financial results, highlighting a significant corporate restructuring including the sale of its manufacturing operations for $122.5 million. This transition to a fully outsourced model has streamlined the company, reducing its workforce to approximately 140 people to focus on its novel therapeutics pipeline. MacroGenics also announced upcoming data presentations for MGC026 and lorigerlimab at ESMO, progress on MGC028 and MGC030, and a strengthened financial position with a cash runway extended through 2028.
Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating
Bernstein has increased its price target for Incyte (NASDAQ: INCY) to $104 from $99, while maintaining a "Market Perform" rating on the stock. This adjustment reflects an updated outlook from the analyst firm. The article also notes recent insider share sales and other analyst target changes for Incyte.
Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear
Prelude Therapeutics (PRLD) saw its stock rally by 10.1% despite still reporting research-stage losses in Q2 2026, driven by a significant narrowing of its net loss and the initiation of modest revenue. While the financial picture appears cleaner due to collaborations, the market is still awaiting clear updates on key clinical milestones for its drug candidates, which remain a point of concern for investors. The article highlights the importance of these clinical advancements for the company's long-term bullish narrative, suggesting that without them, the stock's rally might be precarious.
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Adagene Inc. reported its financial results for the first half of 2026, highlighting significant advancements in its lead program, muzastotug, for microsatellite stable colorectal cancer (MSS CRC) and hepatocellular carcinoma (HCC). The company secured approximately $70 million from a public offering in April 2026, extending its cash runway into late 2028. Clinical data presented at AACR demonstrated compelling efficacy and a favorable safety profile for muzastotug, leading to ongoing Phase 2 trials and new collaborations with Sanofi and Incyte.
Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP)
CRISPR Therapeutics (CRSP) recently reported improved Q2 2026 results with rising revenue of US$10.18 million and a narrower net loss of US$91.15 million, easing immediate cash burn concerns. While these results strengthen the company's position for future clinical and regulatory milestones, they haven't fundamentally altered the market's investment thesis, which remains focused on the long-term success of its gene-editing pipeline. Investors should consider diverse fair value estimates and the impact of sustained losses on future funding.
Insight Wealth Strategies LLC Acquires New Position in Incyte Corporation $INCY
Insight Wealth Strategies LLC has acquired a new stake of 62,175 shares in Incyte Corporation, valued at approximately $7.1 million, during the second quarter. Incyte reported strong quarterly earnings, beating analyst estimates with an EPS of $3.09 and revenue of $1.67 billion. Despite mixed analyst sentiment and a "Hold" consensus rating, several firms have raised their price targets for the biopharmaceutical company.
Adagene’s Cancer Trial Results Expected in 1H 2027
Adagene (Nasdaq: ADAG) reported financial results for the first half of 2026, showing $127.9 million in cash and cash equivalents, extending their runway into late 2028. The company highlighted progress with its lead candidate, muzastotug, including a 31% overall response rate in MSS colorectal cancer and a 66.7% ORR in first-line HCC with various combination therapies. Key clinical trial results, particularly for the randomized Phase 2 MSS CRC trial, are anticipated in the first half of 2027, with potential for a registration trial thereafter.
How Regeneron Pharmaceuticals Went From Cheaper Than Incyte To The Pricier Stock
Regeneron Pharmaceuticals (REGN) now trades at a premium compared to Incyte (INCY), a reversal from a year ago. Regeneron's premium is attributed to its scale, blockbuster drugs like Dupixent and EYLEA HD, and a deep pipeline of approximately 50 clinical programs, despite slower growth than Incyte. Investors must decide whether to choose Regeneron's proven, diversified portfolio or Incyte's faster growth and higher profitability at a lower valuation.
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from Brokerages
Incyte Corporation (NASDAQ:INCY) has received a consensus "Hold" rating from brokerages, with an average 12-month price target of $120.40. The company recently reported strong quarterly earnings, beating estimates with an EPS of $3.09 and revenue of $1.67 billion, a 37.7% increase year-over-year. Despite a recent insider stock sale, institutional investors hold a significant portion of the company's shares.
Bank of America Corp DE Sells 87,913 Shares of Incyte Corporation $INCY
Bank of America Corp DE reduced its stake in Incyte Corporation (NASDAQ:INCY) by 8.8% in the first quarter, selling 87,913 shares while retaining 915,527 shares valued at $86.2 million. Incyte recently reported strong quarterly earnings, beating analyst estimates with an EPS of $3.09 and revenue of $1.67 billion, a 37.7% increase year-over-year. Despite mixed analyst ratings, with a consensus "Hold" and a $120.40 target price, the company's shares opened up 1.8% at $120.56.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte Corporation announced inducement grants to 24 new employees, consisting of restricted stock units and stock options. These awards, totaling 21,556 shares in RSUs and 18,172 shares in stock options, were made under the company's 2024 Inducement Stock Incentive Plan as an incentive for new hires. The grants vest over several years, subject to continued employment, and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Incyte Corporation announced that it granted restricted stock unit awards and stock option awards to 24 new employees as an inducement to their employment. These awards, totaling 21,556 shares in RSUs and options for 18,172 shares, were made under the company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The grants have a vesting commencement date of August 3, 2026, with specific vesting schedules for both RSUs and stock options.
Incyte Corp (INCY) R&D head sells 10,640 shares in plan trade
Pablo J. Cagnoni, President and Global Head of R&D at Incyte (INCY), sold 10,640 shares of common stock at $122.69 per share on August 5, 2026. This transaction was executed under a Rule 10b5-1 trading plan. Following the sale, Cagnoni retains 204,804 shares, which include unvested restricted and performance stock units.
Adagene Inc. (ADRs) (US0053291078.SG) interactive stock chart
This page provides an interactive stock chart and related news for Adagene Inc. (ADRs) under the ticker US0053291078.SG on Yahoo Finance. The stock is currently trading at 3.7800 EUR
24 New Incyte Hires Receive Stock Units Vesting in Four Steps
Incyte Corporation (Nasdaq: INCY) announced it granted restricted stock unit awards for 21,556 shares and stock option awards for 18,172 shares to 24 new employees. These awards, granted under the 2024 Inducement Stock Incentive Plan with a vesting commencement date of August 3, 2026, are an inducement for new hires as per Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, while stock options vest over the first year and then monthly thereafter, both contingent on continued employment.
Incyte Corp (INCY) EVP sells 2,207 shares after option exercise
Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte Corp (INCY), exercised 2,207 employee stock options at $106.47 per share and subsequently sold the same number of common shares at $123.99 per share on August 5, 2026. These transactions were executed under a Rule 10b5-1 trading plan. After the sale, Mayes holds 61,441 direct common shares and 59,537 unvested restricted stock units.
Incyte Corp. stock outperforms competitors on strong trading day
Incyte Corp. (INCY) shares rose 1.84% on Friday, closing at $120.56, outperforming the broader market. This gain broke a two-day losing streak for the company, as the S&P 500 and Dow Jones Industrial Average also saw increases.
Halozyme Therapeutics HALO Surges After Big Earnings Beat And Guidance Hike
Halozyme Therapeutics (HALO) surged by 19.44% after reporting Q2 earnings that significantly beat expectations, with non-GAAP EPS at $2.28 and revenue at $481M. The company also raised its 2026 non-GAAP EPS and revenue guidance above Street estimates, driven by strong royalty growth and new ENHANZE and Hypercon platform partnerships. This performance highlights Halozyme's strong economic model and positions it as a high-growth leader in the biotech industry.
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors
Agios Pharmaceuticals reported a significant revenue increase in Q2 2026, reaching US$44.75 million, up from US$12.46 million a year prior, while net losses slightly narrowed. This growth is driven by the traction of recent approvals and launches, with the FDA's Priority Review of PYRUKYND for sickle cell disease being a key near-term catalyst. Despite increased sales, substantial losses continue, underscoring the company's need to successfully expand its rare-disease franchise to justify current spending and improve its financial outlook.
Oppenheimer raises Incyte stock price target on Vega acquisition
Oppenheimer has increased its price target for Incyte Corp. (NASDAQ:INCY) to $107 from $90, maintaining an Outperform rating after Incyte acquired Vega Therapeutics. The acquisition adds VGA039, a Phase 3-ready Protein S modulator for von Willebrand disease, which Oppenheimer believes could be a significant long-term growth asset exceeding $1 billion and help diversify Incyte's revenue as its key drug, Jakafi, faces loss of exclusivity. This move is seen as strengthening Incyte's hematology franchise and boosting its financial outlook, despite concerns from other analysts about Jakafi's future sales.
Arcus Biosciences (RCUS) Stock Can Casdatifan Carry Mounting Losses
Arcus Biosciences (RCUS) reported Q2 2026 revenue of US$41m against a net loss of US$91m, indicating a substantial decline from the previous year. While the stock initially saw a pop, concerns persist regarding the company's high burn rate, reliance on partners, and concentrated pipeline focused on the casdatifan asset. The article highlights the contrasting bull and bear cases, emphasizing the potential for dilution risk despite the company's cash reserves.
Stagwell’s 10 New Employees Receive Stock Units Vesting Over 3 Years
Stagwell (NASDAQ: STGW) has granted a total of 77,717 restricted stock units (RSUs) to 10 new employees, effective August 6, 2026. These RSUs, convertible into Class A common shares, will vest over two and three years, with accelerated vesting provisions for certain termination events. This move, made under Nasdaq Listing Rule 5635(c)(4), is intended as a material inducement for employment and reflects the company's strategy to attract and retain talent.
Incyte Corp. stock outperforms competitors despite losses on the day
Incyte Corp. (INCY) shares decreased by 1.19% to $118.38 on Thursday, despite a broader market decline where the S&P 500 Index fell 0.18% and the Dow Jones Industrial Average dropped 0.85%. This marks the second consecutive day of losses for Incyte, yet the stock still managed to outperform its competitors relative to the wider market's performance.
Halozyme earnings up next: Can royalty growth hit $1B target?
Halozyme Therapeutics Inc. is reporting second-quarter earnings, with investors keenly watching its partnership momentum and progress toward a $1 billion ENHANZE royalty revenue target. The company has shown strong growth and secured multiple licensing deals, contributing to its stock trading near 52-week highs. Investors will focus on new partnership additions and the sustainability of its growth trajectory.
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
CRISPR Therapeutics AG (NASDAQ:CRSP) reported strong second-quarter revenues of US$10 million, significantly beating estimates by 37%, and a smaller-than-expected loss of US$0.94 per share. Following these results, analysts have raised their revenue forecasts for 2026 to US$54.4 million and slightly reduced loss per share estimates, indicating a bullish outlook. Despite these upgrades, the consensus price target remains unchanged at US$87.17, although individual analyst targets show a wide divergence.
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Pyxis Oncology Inc (PYXS), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that 10 analysts have given the stock a "Buy" trend, with an average price target of $7.70. The article also includes information on recent and projected EPS performance.
Damora Therapeutics earnings on deck as rare blood cancer race heats up
Damora Therapeutics is set to release its second-quarter earnings, with analysts expecting a loss of 44 cents per share. The pre-revenue biotech is advancing its lead rare blood cancer treatment, DMR-001, towards clinical trials, facing competition from Incyte Corp.'s INCA033989. Investors will focus on DMR-001's differentiation in convenience and Type 2 mutCALR efficacy, as well as the company's cash runway given its substantial cash position.
Syndax Pharmaceuticals Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals reported strong commercial growth in Q2 2026, with combined revenue from Revuforj and Niktimvo reaching $115 million. Revuforj sales increased 91% year-over-year, driven by increased treatment duration, while Niktimvo grew 67% year-over-year, expanding its market share in chronic GVHD. The company also highlighted significant pipeline progress with new assets and upcoming data readouts that could unlock multi-billion dollar opportunities, affirming its financial stability and path to profitability.
Incyte Corp (INCY) EVP sells 47,954 shares after exercising options
Patrick A. Mayes, EVP & Chief Scientific Officer of Incyte (INCY), exercised stock options for 45,767 shares and subsequently sold 47,954 shares of common stock on July 31 and August 3, 2026, through a Rule 10b5-1 trading plan. The sales amounted to approximately $5.73 million, with exercise costs around $3.59 million. Mayes's holdings also include 59,537 unvested restricted stock units.
Incyte Corp (INCY) R&D head sells 15,888 shares, retains 215,444
Pablo J. Cagnoni, President and Global Head of R&D at Incyte Corp (INCY), sold 15,888 shares of the company's common stock at $119.70 per share on July 31, 2026. This transaction was conducted under a Rule 10b5-1 trading plan. Following the sale, Cagnoni directly holds 215,444 shares, which includes 183,200 unvested restricted and performance stock units.
